<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Calabrese, Joseph R.</style></author><author><style face="normal" font="default" size="100%">Gulledge, A. Dale</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Thyroid dysfunction and lithium</style></title><secondary-title><style face="normal" font="default" size="100%">Cleveland Clinic Journal of Medicine</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">1983</style></year><pub-dates><date><style  face="normal" font="default" size="100%">1983-03-20 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">32-33</style></pages><volume><style face="normal" font="default" size="100%">50</style></volume><issue><style face="normal" font="default" size="100%">1</style></issue><abstract><style  face="normal" font="default" size="100%">A patient with prelithium TSH and microsomal antibody abnormalities showed diminished thyroid function during lithium treatment but subsequently responded to thyroid supplements while still receiving lithium. This case demonstrates the necessity of routine screening for thyroid microsomal antibody titres before and during lithium treatment. In addition, it suggests that manic depressives with laboratory evidence of hypothyroidism prior to lithium treatment can be safely treated with lithium and thyroid supplements.</style></abstract></record></records></xml>